Health topic

Cervical cancer

Now, 3 clinically validated tests bring greater diagnostic certainty

Challenges remain in current cervical cancer screening approaches that can now be addressed with more advanced technologies.

The molecular and biomarker-based tests in the Roche Cervical Cancer Portfolio bring greater diagnostic certainty to cervical cancer screening to guide clinicians and women along each step, removing ambiguity that can arise in current testing approaches.

Only the Roche Cervical Cancer Portfolio covers the entire spectrum of screening, triage, and diagnostic solutions

SCREEN 
with the cobas® HPV test

hpv

The cobas® HPV test is FDA-approved for all cervical screening indications: ASC-US reflex, co-testing, and primary screening to assess the risk for cervical precancer and cancer. cobas HPV simultaneously provides pooled results on known high-risk HPV genotypes, and individual results on the two highest-risk genotypes, HPV 16 and HPV 18, giving three results in one from a single sample.

Learn more

TRIAGE
with CINtec® PLUS Cytology

cintec-plus

CINtec® PLUS Cytology is the only FDA-approved triage test that uses dual-biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. The co-expression of these two biomarkers is a strong indicator that an HPV infection is undergoing oncogenic transformation.

Learn more

DIAGNOSE
with CINtec® Histology

cintec histology

CINtec® Histology enhances identification of occult cervical lesions that may be missed by H&E or morphologic interpretation alone. The CINtec® Histology test is the only clinically validated test that uses advanced p16 biomarker technology to confirm the presence or absence of cervical lesions due to transforming HPV infections.

Learn more



infographic

 

To learn more about the Roche Cervical Cancer Portfolio
Contact Us

References

  • cobas® HPV test. Package insert v17, US. Roche Diagnostics; 2018.
  • CINtec® PLUS Cytology. Package insert. Roche Diagnostics; 2020.
  • CINtec® Histology 510(k) [package insert v1, US]. Indianapolis, IN: Roche Diagnostics; 2017.
Found 0 results in
Filters
...
    ...